Gardam MA, Keystone EC, Menzies
R, et al. Anti-tumour necrosis factor agents and tuberculosis risk:
mechanisms of action and clinical management. Lancet Infect Dis
2003; 3: 148–55.
Wajant H, Pfi zenmaier K,
Scheurich P. Tumor necrosis factor signaling. Cell Death Differ
2003; 10: 45–65.
Hehlgans T, Pfeff er K. The
intriguing biology of the tumour necrosis factor/tumour necrosis
factor receptor superfamily: players, rules and the games.
Immunology 2005; 115: 1–20.
Baud V, Karin M. Signal
transduction by tumor necrosis factor and its relatives. Trends
Cell Biol 2001; 11: 372–77.
Kriegler M, Perez C, DeFay K,
Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface
cytotoxic transmembrane protein: ramifi cations for the complex
physiology of TNF. Cell 1988; 53: 45–53.
Black RA, Rauch CT, Kozlosky
CJ, et al. A metalloproteinase disintegrin that releases
tumour-necrosis factor-alpha from cells. Nature 1997; 385:
729–33.
Eck MJ, Sprang SR. The
structure of tumor necrosis factor-alpha at 2.6 A resolution.
Implications for receptor binding. J Biol Chem 1989; 264:
17595–605.
Aversa G, Punnonen J, De Vries
JE. The 26-kD transmembrane form of tumor necrosis factor alpha on
activated CD4+ T cell clones provides a costimulatory signal for
human B cell activation. J Exp Med 1993; 177: 1575–85.
Harashima S, Horiuchi T, Hatta
N, et al. Outside-to-inside signal through the membrane TNF-alpha
induces E-selectin (CD62E) expression on activated human CD4+ T
cells. J Immunol 2001; 166: 130–36.
Mitoma H, Horiuchi T, Hatta N,
et al. Infl iximab induces potent anti-infl ammatory responses by
outside-to-inside signals through transmembrane TNF-alpha.
Gastroenterology 2005; 128: 376–92.
Pfeff er K, Matsuyama T, Kundig
TM, et al. Mice defi cient for the 55 kd tumor necrosis factor
receptor are resistant to endotoxic shock, yet succumb to L
monocytogenes infection. Cell 1993; 73: 457–67.
Peschon JJ, Torrance DS,
Stocking KL, et al. TNF receptor-deficient mice reveal divergent
roles for p55 and p75 in several models of infl ammation. J Immunol
1998; 160: 943–52.
Grell M, Douni E, Wajant H, et
al. The transmembrane form of tumor necrosis factor is the prime
activating ligand of the 80 kDa tumor necrosis factor receptor.
Cell 1995; 83: 793–802.
Pfeff er K. Biological
functions of tumor necrosis factor cytokines and their receptors.
Cytokine Growth Factor Rev 2003; 14: 185–91.
Roach DR, Bean AG, Demangel C,
France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction
essential for cell recruitment, granuloma formation, and clearance
of mycobacterial infection. J Immunol 2002; 168:
4620–27.
Flynn JL, Goldstein MM, Chan J,
et al. Tumor necrosis factor-alpha is required in the protective
immune response against Mycobacterium tuberculosis in mice.
Immunity 1995; 2: 561–72.
Mohan VP, Scanga CA, Yu K, et
al. Eff ects of tumor necrosis factor alpha on host immune response
in chronic persistent tuberculosis: possible role for limiting
pathology. Infect Immun 2001; 69: 1847–55.
Bean AG, Roach DR, Briscoe H,
et al. Structural defi ciencies in granuloma formation in TNF
gene-targeted mice underlie the heightened susceptibility to
aerosol Mycobacterium tuberculosis infection, which is not
compensated for by lymphotoxin. J Immunol 1999; 162:
3504–11.
Flynn JL, Chan J, Triebold KJ,
Dalton DK, Stewart TA, Bloom BR. An essential role for interferon
gamma in resistance to Mycobacterium tuberculosis infection. J Exp
Med 1993; 178: 2249–54.
Saunders BM, Tran S, Ruuls S,
Sedgwick JD, Briscoe H, Britton WJ. Transmembrane TNF is suffi
cient to initiate cell migration and granuloma formation and
provide acute, but not long-term, control of Mycobacterium
tuberculosis infection. J Immunol 2005; 174: 4852–59.
Erickson SL, de Sauvage FJ,
Kikly K, et al. Decreased sensitivity to tumour-necrosis factor but
normal T-cell development in TNF receptor-2-defi cient mice. Nature
1994; 372: 560–33.
Everest P, Roberts M, Dougan G.
Susceptibility to Salmonella typhimurium infection and eff
ectiveness of vaccination in mice defi cient in the tumor necrosis
factor alpha p55 receptor. Infect Immun 1998; 66:
3355–64.
Rothe J, Lesslauer W, Lotscher
H, et al. Mice lacking the tumour necrosis factor receptor 1 are
resistant to TNF-mediated toxicity but highly susceptible to
infection by Listeria monocytogenes. Nature 1993; 364:
798–802.
Ehlers S, Holscher C, Scheu S,
et al. The lymphotoxin beta receptor is critically involved in
controlling infections with the intracellular pathogens
Mycobacterium tuberculosis and Listeria monocytogenes. J Immunol
2003; 170: 5210–18.
Roach DR, Briscoe H, Saunders
B, France MP, Riminton S, Britton WJ. Secreted lymphotoxin-alpha is
essential for the control of an intracellular bacterial infection.
J Exp Med 2001; 193: 239–46.
Bopst M, Garcia I, Guler R, et
al. Diff erential eff ects of TNF and LTalpha in the host defense
against M bovis BCG. Eur J Immunol 2001; 31: 1935–43.
Jacobs M, Brown N, Allie N,
Ryff el B. Fatal Mycobacterium bovis BCG infection in
TNF-LT-alpha-defi cient mice. Clin Immunol 2000; 94:
192–99.
Olleros ML, Guler R, Vesin D,
et al. Contribution of transmembrane tumor necrosis factor to host
defense against Mycobacterium bovis bacillus Calmette-guerin and
Mycobacterium tuberculosis infections. Am J Pathol 2005; 166:
1109–20.
Olleros ML, Guler R, Corazza N,
et al. Transmembrane TNF induces an effi cient cell-mediated
immunity and resistance to Mycobacterium bovis bacillus
Calmette-Guerin infection in the absence of secreted TNF and
lymphotoxin-alpha. J Immunol 2002; 168: 3394–401.
Alexopoulou L, Kranidioti K,
Xanthoulea S, et al. Transmembrane TNF protects mutant mice against
intracellular bacterial infections, chronic infl ammation and
autoimmunity. Eur J Immunol 2006; 36: 2768–80.
Musicki K, Briscoe H, Tran S,
Britton WJ, Saunders BM. Diff erential requirements for soluble and
transmembrane tumor necrosis factor in the immunological control of
primary and secondary Listeria monocytogenes infection. Infect
Immun 2006; 74: 3180–89.
Torres D, Janot L, Quesniaux
VF, et al. Membrane tumor necrosis factor confers partial
protection to listeria infection. Am J Pathol 2005; 167:
1677–87.
Abbott Laboratories. Humira
prescribing information, 2007. Abbott Park, IL, USA: Abbott
Laboratories. http://www.rxabbott. com/pdf/humira.pdf (accessed Aug
13, 2008).
Centocor. Infl iximab
(Remicade) prescribing information, 2007. Malvern PA, USA:
Centocor. http://www.remicade.com/remicade/ assets/HCP_PPI.pdf
(accessed Aug 13, 2008).
Baughman RP, Drent M, Kavuru M,
et al. Infl iximab therapy in patients with chronic sarcoidosis and
pulmonary involvement. Am J Respir Crit Care Med 2006; 174:
795–802.
Saleh S, Ghodsian S, Yakimova
V, Henderson J, Sharma OP. Eff ectiveness of infl iximab in
treating selected patients with sarcoidosis. Respir Med 2006; 100:
2053–59.
Rossman MD, Newman LS, Baughman
RP, et al. A double-blinded, randomized, placebo-controlled trial
of infl iximab in subjects with active pulmonary sarcoidosis.
Sarcoidosis Vasc Diff use Lung Dis 2006; 23: 201–08.
Sandborn WJ, Feagan BG, Stoinov
S, et al. Certolizumab pegol for the treatment of Crohn's disease.
N Engl J Med 2007; 357: 228–38.
Keystone E, Mason D, Combe B.
The anti-TNF certolizumab pegol in combination with methotrexate is
signifi cantly more eff ective than methotrexate alone in the
treatment of patients with active rheumatoid arthritis: preliminary
results from the RAPID 1 study. Ann Rheum Dis 2007; 66 (suppl 2):
55.
Smolen J, Brezezicki J, Mason
D, Kavanaugh A. Effi cacy and safety of certolizumab pegol in
combination with methotrexate (MTX) in patients with active
rheumatoid arthritis despite MTX therapy: results from the RAPID 2
study. Ann Rheum Dis 2007; 66 (suppl 2): 187.
St Clair EW, Wagner CL,
Fasanmade AA, et al. The relationship of serum infl iximab
concentrations to clinical improvement in rheumatoid arthritis:
results from ATTRACT, a multicenter, randomized, double-blind,
placebo-controlled trial. Arthritis Rheum 2002; 46:
1451–59.
Nestorov I. Clinical
pharmacokinetics of TNF antagonists: how do they diff er? Semin
Arthritis Rheum 2005; 34: 12–18.
Amgen. Enbrel prescribing
information, 2005. Thousand Oaks, CA, and Madison, NJ, USA: Amgen
and Wyeth Pharmaceuticals.
http://www.enbrel.com/prescribing-information.jsp (accessed Aug 13,
2008).
Sandborn WJ, Hanauer SB, Katz
S, et al. Etanercept for active Crohn's disease: a randomized,
double-blind, placebo-controlled trial. Gastroenterology 2001; 121:
1088–94.
Utz JP, Limper AH, Kalra S, et
al. Etanercept for the treatment of stage II and III progressive
pulmonary sarcoidosis. Chest 2003; 124: 177–85.
Wajdula J, Macpeek D, Lim S,
Hamza S, Fatenejad S. Incidence of tuberculosis is low in patients
receiving etanercept therapy for the treatment of rheumatoid
arthritis: results from a combined analysis of US and ex-US
double-blind trials and their open label extensions. Ann Rheum Dis
2007; 66 (suppl 2): 195.
Infuso A, Falzon D. European
survey of BCG vaccination policies and surveillance in children,
2005. Euro Surveill 2006; 11: 6–11.
WHO. Global tuberculosis
control—surveillance, planning, fi nancing. Geneva: World Health
Organization, 2007. WHO/HTM/ TB/2007.376.
http://www.who.int/tb/publications/global_
report/2007/en/index.html (accessed Aug 13, 2008).
Jajosky RA, Hall PA, Adams DA,
et al. Summary of notifi able diseases—United States, 2004. MMWR
Morb Mortal Wkly Rep 2006; 53: 1–79.
Nardell EA, Wallis RS. Here
today—gone tomorrow: the case for transient acute tuberculosis
infection. Am J Respir Crit Care Med 2006; 174:
734–35.
Coaccioli S, Di Cato L, Marioli
D, et al. Impaired cutaneous cell-mediated immunity in newly
diagnosed rheumatoid arthritis. Panminerva Med 2000; 42:
263–66.
Wallis RS, Broder MS, Wong JY,
Hanson JY, Beenhouwer DO. Granulomatous infectious diseases
associated with TNF antagonists. Clin Infect Dis 2004; 38:
1261–65.
Wallis RS, Broder MS, Wong JY,
Beenhouwer DO. Granulomatous infections due to tumor necrosis
factor blockade: correction. Clin Infect Dis 2004; 39:
1254–56.
Bergstrom L, Yocum DE, Ampel
NM, et al. Increased risk of coccidioidomycosis in patients treated
with TNF antagonists. Arthritis Rheum 2004; 50:
1959–66.
Brassard P, Kezouh A, Suissa S.
Antirheumatic drugs and the risk of tuberculosis. J Infect Dis
2006; 43: 1532–37.
Wallis, RS. Tumor necrosis
factor-alpha inhibitors and mycobacterial infections. In: Rose BD,
ed. UpToDate. Waltham, MA: UpToDate, 2008. http://www.uptodate.com
(accessed Aug 29, 2008).
Wolfe F, Michaud K, Anderson J,
Urbansky K. Tuberculosis infection in patients with rheumatoid
arthritis and the eff ect of infl iximab therapy. Arthritis Rheum
2004; 50: 372–79.
Dixon WG, Watson K, Lunt M,
Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection,
including site-specifi c and bacterial intracellular infection, in
rheumatoid arthritis patients receiving anti-tumor necrosis factor
therapy: results from the British Society for Rheumatology
Biologics Register. Arthritis Rheum 2006; 54: 2368–76.
Askling J, Fored CM, Brandt L,
et al. Risk and case characteristics of tuberculosis in rheumatoid
arthritis associated with tumor necrosis factor antagonists in
Sweden. Arthritis Rheum 2005; 52: 1986–92.
Listing J, Strangfeld A, Kary
S, et al. Infections in patients with rheumatoid arthritis treated
with biologic agents. Arthritis Rheum 2005; 52:
3403–12.
Carmona L, Hernandez-Garcia C,
Vadillo C, et al. Increased risk of tuberculosis in patients with
rheumatoid arthritis. J Rheumatol 2003; 30: 1436–39.
Gomez-Reino JJ, Carmona L,
Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis
with tumor necrosis factor inhibitors may predispose to signifi
cant increase in tuberculosis risk: a multicenter
active-surveillance report. Arthritis Rheum 2003; 48:
2122–27.
Carmona L, Gomez-Reino JJ,
Rodriguez-Valverde V, et al. Eff ectiveness of recommendations to
prevent reactivation of latent tuberculosis infection in patients
treated with tumor necrosis factor antagonists. Arthritis Rheum
2005; 52: 1766–72.
Fonseca JE, Canhao H, Silva C.
Tuberculosis in rheumatic patients treated with tumour necrosis
factor alpha antagonists: the Portuguese experience. Acta Reumatol
Port 2006; 31: 247–53 (in Portuguese).
Salmon D, Tubach F, Ravaud P. A
risk of tuberculosis persists in patients treated with anti TNF-a
antagonist therapy despite prophylactic guidelines: identifi cation
of main risk factors. 17th European Congress of Clinical
Microbiology and Infectious Diseases and 25th Interntational
Congress of Chemotherapy; Munich, Germany; March 31–April 3, 2007.
Abstract O471.
Tubach F, Salmon-Ceron D,
Ravaud P, Mariette X. The RATIO observatory: French registry of
opportunistic infections, severe bacterial infections, and
lymphomas complicating anti-TnFalpha therapy. Joint Bone Spine
2005; 72: 456–60.
Keane J, Gershon S, Wise RP, et
al. Tuberculosis associated with infl iximab, a tumor necrosis
factor alpha-neutralizing agent. N Engl J Med 2001; 345:
1098–104.
Mines D, Novelli L.
Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis
2007; 44: 619–20.
Subramanyan GS, Yokoe DS,
Sharnprapai S, Nardell E, McCray E, Platt R. Using automated
pharmacy records to assess the management of tuberculosis. Emerg
Infect Dis 1999; 5: 788–91.
Wallis RS. Mathematical
modeling of the cause of tuberculosis during tumor necrosis factor
blockade. Arthritis Rheum 2008; 58: 947–52.
Plessner HL, Lin PL, Kohno T,
et al. Neutralization of tumor necrosis factor (TNF) by antibody
but not TNF receptor fusion molecule exacerbates chronic murine
tuberculosis. J Infect Dis 2007; 195: 1643–50.
Korth-Bradley JM, Rubin AS,
Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept
in healthy volunteers. Ann Pharmacother 2000; 34:
161–64.
Nesbitt AM, Gramlick A, Fossati
G, Henry AJ, Stephens PE. Assessment of the affi nity for soluble
TNF and the neutralising potency against soluble and membrane TNF
of the anti-TNF agents certolizumab pegol, adalimumab, etanercept
and infl iximab. Ann Rheum Dis 2006; 65 (suppl 2):
456.
Scallon B, Cai A, Solowski N,
et al. Binding and functional comparisons of two types of tumor
necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:
418–26.
Santora LC, Kaymakcalan Z,
Sakorafas P, Krull IS, Grant K. Characterization of noncovalent
complexes of recombinant human monoclonal antibody and antigen
using cation exchange, size exclusion chromatography, and BIAcore.
Anal Biochem 2001; 299: 119–29.
Rigby WF. Drug insight: diff
erent mechanisms of action of tumor necrosis factor
antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol
2007; 3: 227–33.
Saint Marcoux B, De Bandt M.
Vasculitides induced by TNFalpha antagonists: a study in 39
patients in France. Joint Bone Spine 2006; 73: 710–13.
Mohan N, Edwards ET, Cupps TR,
et al. Leukocytoclastic vasculitis associated with tumor necrosis
factor-alpha blocking agents. J Rheumatol 2004; 31:
1955–58.
Nesbitt AM, Fossati G. In vitro
complement-dependent cytotoxicity and antibody-dependent cellular
cytotoxicity by the anti-TNF agents certolizumab pegol, adalimumab,
etanercept, and infl iximab. Ann Rheum Dis 2006; 65 (suppl 2):
455.
Scallon BJ, Moore MA, Trinh H,
Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody
cA2 binds recombinant transmembrane TNF-alpha and activates immune
eff ector functions. Cytokine 1995; 7: 251–59.
Saliu O, Sofer C, Stein DS,
Schwander SK, Wallis RS. Tumor necrosis factor blockers: diff
erential eff ects on mycobacterial immunity. J Infect Dis 2006;
194: 486–92.
ten Hove T, van Montfrans C,
Peppelenbosch MP, van Deventer SJ. Infl iximab treatment induces
apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut
2002; 50: 206–11.
Van den Brande JM, Braat H, van
den Brink GR, et al. Infl iximab but not etanercept induces
apoptosis in lamina propria T-lymphocytes from patients with
Crohn's disease. Gastroenterology 2003; 124: 1774–85.
Di Sabatino A, Ciccocioppo R,
Cinque B, et al. Defective mucosal T cell death is sustainably
reverted by infl iximab in a caspase dependent pathway in Crohn's
disease. Gut 2004; 53: 70–77.
Van den Brande JM, Koehler TC,
Zelinkova Z, et al. Prediction of antitumour necrosis factor
clinical effi cacy by real-time visualisation of apoptosis in
patients with Crohn's disease. Gut 2007; 56: 509–17.
Shen C, Assche GV, Colpaert S,
et al. Adalimumab induces apoptosis of human monocytes: a
comparative study with infl iximab and etanercept. Aliment
Pharmacol Ther 2005; 21: 251–58.
Kirchner S, Holler E, Haff ner
S, Andreesen R, Eissner G. Eff ect of diff erent tumor necrosis
factor (TNF) reactive agents on reverse signaling of membrane
integrated TNF in monocytes. Cytokine 2004; 28: 67–74.
Catrina AI, Trollmo C, af Klint
E, et al. Evidence that anti-tumor necrosis factor therapy with
both etanercept and infl iximab induces apoptosis in macrophages,
but not lymphocytes, in rheumatoid arthritis joints: extended
report. Arthritis Rheum 2005; 52: 61–72.
Malaviya R, Sun Y, Tan JK, et
al. Etanercept induces apoptosis of dermal dendritic cells in
psoriatic plaques of responding patients. J Am Acad Dermatol 2006;
55: 590–97.
Tan JK, Aphale A, Malaviya R,
Sun Y, Gottlieb AB. Mechanisms of action of etanercept in
psoriasis. J Investig Dermatol Symp Proc 2007; 12:
38–45.
Agnholt J, Kaltoft K. Infl
iximab downregulates interferon-gamma production in activated gut
T-lymphocytes from patients with Crohn's disease. Cytokine 2001;
15: 212–22.
Kawashima M, Miossec P. Eff ect
of treatment of rheumatoid arthritis with infl iximab on IFN gamma,
IL4, T-bet, and GATA-3 expression: link with improvement of
systemic infl ammation and disease activity. Ann Rheum Dis 2005;
64: 415–18.
Nissinen R, Leirisalo-Repo M,
Peltomaa R, Palosuo T, Vaarala O. Cytokine and chemokine receptor
profi le of peripheral blood mononuclear cells during treatment
with infl iximab in patients with active rheumatoid arthritis. Ann
Rheum Dis 2004; 63: 681–87.
Haider AS, Cardinale IR, Whynot
JA, Krueger JG. Eff ects of etanercept are distinct from infl
iximab in modulating proinfl ammatory genes in activated human
leukocytes. J Investig Dermatol Symp Proc 2007; 12:
9–15.
Hamdi H, Mariette X, Godot V,
et al. Inhibition of anti-tuberculosis T-lymphocyte function with
tumour necrosis factor antagonists. Arthritis Res Ther 2006; 8:
R114.
Daniel TM, Debanne SM.
Estimation of the annual risk of tuberculosis infection for white
men in the United States. J Infect Dis 1997; 175:
1535–37.
Wallis RS. Mathematical
modeling of the cause of tuberculosis during tumor necrosis factor
blockade. Arthritis Rheum 2008; 58: 947–52.
Brewer MA, Edwards KM, Palmer
PS, Hinson HP. Bacille Calmette-Guerin immunization in normal
healthy adults. J Infect Dis 1994; 170: 476–79.
Mudido PM, Guwatudde D,
Nakakeeto MK, et al. The eff ect of bacille Calmette-Guerin
vaccination at birth on tuberculin skin test reactivity in Ugandan
children. Int J Tuberc Lung Dis 1999; 3: 891–95.
Behr MA, Wilson MA, Gill WP, et
al. Comparative genomics of BCG vaccines by whole-genome DNA
microarray. Science 1999; 284: 1520–23.
Brock I, Weldingh K, Leyten EM,
Arend SM, Ravn P, Andersen P. Specifi c T-cell epitopes for
immunoassay-based diagnosis of Mycobacterium tuberculosis
infection. J Clin Microbiol 2004; 42: 2379–87.
Ponce de Leon D,
Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an
interferon-gamma assay with tuberculin skin testing for detection
of tuberculosis (TB) infection in patients with rheumatoid
arthritis in a TB-endemic population. J Rheumatol 2008; 35:
776–81.
Lalvani A, Nagvenkar P, Udwadia
Z, et al. Enumeration of T cells specifi c for RD1-encoded antigens
suggests a high prevalence of latent Mycobacterium tuberculosis
infection in healthy urban Indians. J Infect Dis 2001; 183:
469–77.
Ponce de Leon D,
Acevedo-Vasquez E, Sanchez-Torres A, et al. Attenuated response to
purifi ed protein derivative in patients with rheumatoid arthritis:
study in a population with a high prevalence of tuberculosis. Ann
Rheum Dis 2005; 64: 1360–61.
Paimela L,
Johansson-Stephansson EA, Koskimies S, Leirisalo-Repo M. Depressed
cutaneous cell-mediated immunity in early rheumatoid arthritis.
Clin Exp Rheumatol 1990; 8: 433–37.
Richards NM, Nelson KE, Batt
MD, Hackbarth D, Heidenreich JG. Tuberculin test conversion during
repeated skin testing, associated with sensitivity to
nontuberculous mycobacteria. Am Rev Respir Dis 1979; 120:
59–-65.
Thompson NJ, Glassroth JL,
Snider DE, Farer LS. The booster phenomenon in serial tuberculin
testing. Am Rev Respir Dis 1979; 119: 587–97.
WHO. Anti-tuberculosis drug
resistance in the world: report no 4. Geneva: World Health
Organization, 2008. WHO/HTM/ TB/2008.394.
http://www.who.int/tb/publications/2008/drs_ report4_26feb08.pdf
(accessed Aug 13, 2008).
Comstock GW, Baum C, Snider DE.
Isoniazid prophylaxis among Alaskan eskimos: a fi nal report of the
Bethel isoniazid studies. Am Rev Respir Dis 1979; 119:
827–30.
Anon. Effi cacy of various
durations of isoniazid preventive therapy for tuberculosis: fi ve
years of follow-up in the IUAT trial. International Union Against
Tuberculosis Committee on Prophylaxis. Bull World Health Organ
1982; 60: 555–64.
Higuchi K, Harada N, Fukazawa
K, Mori T. Relationship between whole-blood interferon-gamma
responses and the risk of active tuberculosis. Tuberculosis (Edinb)
2008; 88: 244–48.
Edwards LB, Acquaviva FA,
Livesay VT. Identifi cation of tuberculous infected: dual tests and
density of reaction. Am Rev Respir Dis 1973; 108:
1334–39.
Stout JE. Safety of rifampin
and pyrazinamide for the treatment of latent tuberculosis
infection. Expert Opin Drug Saf 2004; 3: 187–98.
Saukkonen J. Rifampin and
pyrazinamide for latent tuberculosis infection: clinical trials and
general practice. Clin Infect Dis 2004; 39: 566–68.
Zhang LX, Tu DH, He GX, et al.
Risk of tuberculosis infection and tuberculous meningitis after
discontinuation of Bacillus Calmette-Guerin in Beijing. Am J Respir
Crit Care Med 2000; 162: 1314–17.
Kolappan C, Gopi PG, Subramani
R, et al. Estimation of annual risk of tuberculosis infection
(ARTI) among children aged 1–9 years in the south zone of India.
Int J Tuberc Lung Dis 2004; 8: 418–23.
Huang F, Wang L, Zhang J, Deng
X, Guo J, Zhang Y. Risk of tuberculosis in a Chinese registry of
rheumatoid arthritis and ankylosing spondylitis for tumour necrosis
factor-a antagonists. J Rheumatol 2006; 9: 170–74.
Matsumoto T, Tanaka T, Kawase
I. Infl iximab for rheumatoid arthritis in a patient with
tuberculosis. N Engl J Med 2006; 355: 740–41.
Wallis RS, Kyambadde P, Johnson
JL, et al. A study of the safety, immunology, virology, and
microbiology of adjunctive etanercept in HIV-1-associated
tuberculosis. AIDS 2004; 18: 257–64.
Mayanja-Kizza H, Jones-Lopez
EC, Okwera A, et al. Immunoadjuvant therapy for HIV-associated
tuberculosis with prednisolone: a phase II clinical trial in
Uganda. J Infect Dis 2005; 191: 856–65.
Wallis RS. Reconsidering
adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005; 41:
201–08.
Karakousis PC, Yoshimatsu T,
Lamichhane G, et al. Dormancy phenotype displayed by extracellular
Mycobacterium tuberculosis within artifi cial granulomas in mice. J
Exp Med 2004; 200: 647–57.
Arend SM, Leyten EM, Franken
WP, Huisman EM, van Dissel JT. A patient with de novo tuberculosis
during anti-tumor necrosis factor-alpha therapy illustrating
diagnostic pitfalls and paradoxical response to treatment. Clin
Infect Dis 2007; 45: 1470–75.
Garcia Vidal C, Fernandez SR,
Lacasa JM, Salavert M, Carballeira MR, Garau J. Paradoxical
response to anti-tuberculous therapy in infl iximab-treated
patients with disseminated tuberculosis. Clin Infect Dis 2005; 40:
756–59.
Blackmore TK, Manning L, Taylor
W, Wallis RS. Therapeutic use of infl iximab in tuberculosis to
control severe paradoxical reaction of the brain and lymph nodes.
Clin Infect Dis 2008 (in press).